Even though some regimens may be relatively safe, in our study, only one-third of patents with late-stage CKD received chemotherapy and less than half of Her-2-enriched breast cancer patients with late-stage CKD received anti-Her-2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.